Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02892682
Other study ID # UF 9650
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 31, 2016
Est. completion date May 10, 2023

Study information

Verified date November 2023
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to compare groups with isolated wheals, isolated angioedema, combination of both and hereditary angioedema in terms of coagulation pathways.


Description:

Previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to compare groups with isolated wheals, isolated angioedema, combination of both and hereditary angioedema in terms of coagulation pathways. the main objective is to highlight a difference between the rates of different coagulation factors in the 3 groups presenting different categories of angiodemes patients with a group of patients with isolated superficial chronic urticaria


Recruitment information / eligibility

Status Terminated
Enrollment 96
Est. completion date May 10, 2023
Est. primary completion date May 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - recurrent angioderma Exclusion Criteria: - anticoagulant therapy, diseases of hemostasis

Study Design


Related Conditions & MeSH terms

  • Angioedema
  • Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency
  • Urticaria

Intervention

Other:
BLOOD TEST


Locations

Country Name City State
France Montpellier University Hospital Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Levels of several coagulation pathway markers in each group 24 Months